
Get exclusive money-saving offers and guides
Straight to your inbox
Posted
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Sinovac Biotech Ltd is a biotechnology business with stocks listed in the US. Sinovac Biotech Ltd shares (SVA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$6.47 – the same closing value as a week prior. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$6.47 - US$6.47 |
---|---|
50-day moving average | US$6.47 |
200-day moving average | US$6.47 |
Target price | US$6 |
PE ratio | 38.5119 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$0.168 |
Standard brokerage - US shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $6.47 on 2021-01-22
1 week (2021-01-15) | 0% |
---|---|
1 month (2020-12-24) | 0% |
3 months (2020-10-23) | 0% |
6 months (2020-07-24) | 0% |
1 year (2020-01-24) | 0% |
---|---|
2 years (2019-01-25) | 1.09% |
3 years (2018-01-25) | -21.86% |
5 years (2016-01-25) | 36.79% |
Valuing Sinovac Biotech Ltd stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sinovac Biotech Ltd's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sinovac Biotech Ltd's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, Sinovac Biotech Ltd shares trade at around 39x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Sinovac Biotech Ltd's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$51.4 million.
The EBITDA is a measure of a Sinovac Biotech Ltd's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | US$264.3 million |
---|---|
Operating margin TTM | 18.03% |
Gross profit TTM | US$213.6 million |
Return on assets TTM | 5.57% |
Return on equity TTM | 13.11% |
Profit margin | 9.36% |
Book value | 3.098 |
Market capitalisation | US$460.2 million |
TTM: trailing 12 months
There are currently 199,773 Sinovac Biotech Ltd shares held short by investors – that's known as Sinovac Biotech Ltd's "short interest". This figure is 0% down from 199,773 last month.
There are a few different ways that this level of interest in shorting Sinovac Biotech Ltd shares can be evaluated.
Sinovac Biotech Ltd's "short interest ratio" (SIR) is the quantity of Sinovac Biotech Ltd shares currently shorted divided by the average quantity of Sinovac Biotech Ltd shares traded daily (recently around inf billion). Sinovac Biotech Ltd's SIR currently stands at 0. In other words for every 100,000 Sinovac Biotech Ltd shares traded daily on the market, roughly 0 shares are currently held short.
However Sinovac Biotech Ltd's short interest can also be evaluated against the total number of Sinovac Biotech Ltd shares, or, against the total number of tradable Sinovac Biotech Ltd shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sinovac Biotech Ltd's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sinovac Biotech Ltd shares in existence, roughly 0 shares are currently held short) or 0.0028% of the tradable shares (for every 100,000 tradable Sinovac Biotech Ltd shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sinovac Biotech Ltd.
Find out more about how you can short Sinovac Biotech Ltd stock.
We're not expecting Sinovac Biotech Ltd to pay a dividend over the next 12 months.
Over the last 12 months, Sinovac Biotech Ltd's shares have ranged in value from as little as US$6.47 up to US$6.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sinovac Biotech Ltd's is 0.0809. This would suggest that Sinovac Biotech Ltd's shares are less volatile than average (for this exchange).
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella, pneumococcal polysaccharide, and Sabin inactivated polio vaccines. Further, it is developing rubella vaccine; Sabin-strain inactivated polio vaccine; Sars-coVv-2 (COVID-19) vaccine; and quadrivalent influenza vaccine. Sinovac Biotech Ltd. has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; Dynavax Technologies Corporation to develop a vaccine to prevent COVID-19; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. The company was founded in 1999 and is based in Beijing, the People's Republic of China.
From the best overall face moisturiser for dry skin to the best body moisturiser, hand moisturiser and tinted moisturiser for dry skin, these are the best 7 moisturisers for dry skin you can buy in Australia right now.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.